Have Rite Aid’s Days of Excitement Come to an End?

Rite Aid has been the best-performing pharmacy of the last two years, but what about looking ahead?

Jun 23, 2014 at 2:00PM

Rite Aid (NYSE:RAD) has been full of surprises since 2013, and therefore its stock has soared 500%. However, its first quarter lacked any such surprises. So in looking ahead, is Rite Aid still a stock that can outperform peers CVS Caremark and Walgreen (NASDAQ:WBA)?

A history of surprises
On Dec. 20, 2012 Rite Aid reported its first quarter of net income in half a decade, which thereby initiated what has become a tremendous 16 months of stock gains. The profit served as a pleasant surprise for a company that many thought was destined for bankruptcy, and it was then followed by seven consecutive quarters of net income.

Rite Aid's improvement in margins has been a result of increased generic-drug introductions. These drugs are cheaper to purchase, allow for larger markups, and are often bought in bulk, thus creating savings on logistical costs. Therefore, this process continued to drive margins even higher, which thereby led to higher guidance from the company, another pleasant surprise.

This domino effect took another step forward as new-found profits gave Rite Aid the capital to continue its store-remodeling program, which then drove traffic higher. As a result, Rite Aid has returned to growth, yet another surprise.

Rite Aid now projects that this growth will be ongoing as its new initiatives have had a positive effect. Most notably Rite Aid has increased the use of technology by using devices like iPads to become more useful to consumes. Its Health Alliance program for the elderly and ill has made it easier for physicians, pharmacists, and insurance companies to work as one, making Rite Aid a top destination spot for this population. Lastly, its new distribution partnership has cut inventories and has Rite Aid better positioned for an industry with higher generic volume. 

So what's wrong?
The problem for Rite Aid is that after a 500% gain since 2013, the stock has priced increased margins and revenue growth into the valuation of the company. Rite Aid released a very strong first quarter, with $41.4 million in net income, total revenue growth of 2.7%, and a 4.3% boost in its pharmacy same-store sales. Unfortunately, these things were expected, and shares fell more than 3% on the news. It seems that stock gains may become more difficult as increased optimism is priced in.

What's next for these competitors?
In looking ahead, Rite Aid is no longer full of surprises and will thereby trade according to its fundamental improvements. While it remains significantly discounted to peers CVS and Walgreen on a price-to-sales basis, Rite Aid is not growing nearly as fast nor is it as profitable. Therefore, accelerated revenue growth beyond the expected 2% could lead to larger returns, but anything equal likely means a flat-performing stock.

Wag And Alliance

Source: WSJ

If Walgreen buys Alliance Boots, it'll get Boots' $36 billion in annual revenue, $1.3 billion in profit, and a new market in the United Kingdom. Additionally, Walgreen would gain the UK's corporate tax rate of 21% versus 35% in the U.S., saving the company hundreds of millions a year in tax-related expenses.

Not to mention, Walgreen creates the majority of its revenue from prescriptions while Alliance operates mainly as a pharmacy wholesaler. Therefore by combining, Walgreen and Alliance inventories can be utilized more efficiently and distribution channels can be perfected, and Walgreen can make an attempt at becoming a worldwide company, which is clearly a larger market. 

Foolish thoughts
Rite Aid and CVS might very well trade higher long term, but if so it will be due to fundamental improvements that exceed Wall Street's expectations. With that said, Walgreen has since become the exciting company within this space, and given the benefits of an Alliance Boots acquisition, I think investors should feel pretty good about the long-term direction of the stock.

Aside from Walgreen and Rite Aid, here's another way to profit from changes in the health-care space
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Brian Nichols owns shares of Rite Aid. The Motley Fool recommends CVS Caremark. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers